Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Jasper Therapeutics Inc. (JSPR)

Jasper Therapeutics Inc. (JSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Author
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus MarketBeat - Thu Jul 13, 2023

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

GILD : 68.40 (-0.35%)
AMGN : 310.77 (-0.08%)
BMY : 40.45 (-2.06%)
NVS : 106.44 (-0.09%)
BGNE : 143.93 (-0.66%)
JSPR : 22.78 (-1.56%)
VIGL : 4.01 (-8.35%)
ALVR : 0.7350 (+0.68%)
RCUS : 14.65 (-4.25%)
FLACU : 9.50 (+2.48%)
Wall Street - NYSE Stock Market American Flag
S&P Futures Tick Lower As Investors Await Fed Rate Decision, Snap Plunges on Weak Outlook Barchart - Wed Feb 1, 2023

March S&P 500 futures (ESH23) are trending down -0.41% this morning after three major U.S. benchmark indices finished the regular session higher as market participants weighed up economic data and a slew...

ESH23 : 3,957.05s (-0.09%)
GM : 46.95 (+0.58%)
PHM : 104.52 (-1.61%)
SNAP : 16.26 (+1.50%)
HUSQB.S.DX : 87.150 (+2.22%)
WDC : 78.05 (+2.19%)
EA : 138.88 (+1.14%)
AMD : 164.31 (+4.20%)
JSPR : 22.78 (-1.56%)
TSHA : 2.16 (-4.42%)
Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium Globe Newswire - Thu Jun 23, 2022

REDWOOD CITY, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with...

JSPR : 22.78 (-1.56%)
Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022 Globe Newswire - Mon Jun 6, 2022

REDWOOD CITY, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell...

JSPR : 22.78 (-1.56%)
Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update Globe Newswire - Thu May 12, 2022

Successful meeting with the FDA; the Company intends to initiate registrational studies in MDS and AML in Q1-2023Clinical data from the Phase 1 study of...

JSPR : 22.78 (-1.56%)
Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting Globe Newswire - Thu Apr 28, 2022

Based on positive feedback provided by FDA on key clinical design details Jasper plans to initiate registrational studies in AML and MDS patients...

JSPR : 22.78 (-1.56%)
Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation Globe Newswire - Tue Apr 26, 2022

JSP191 is well tolerated with no treatment-related severe adverse events in 24 patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)...

JSPR : 22.78 (-1.56%)
Jasper Therapeutics to Host In-Person Key Opinion Leader Webinar on Transforming Hematopoietic Stem Cell Therapies Globe Newswire - Fri Apr 22, 2022

REDWOOD CITY, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell...

JSPR : 22.78 (-1.56%)
Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting Globe Newswire - Thu Mar 31, 2022

REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell...

JSPR : 22.78 (-1.56%)
Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Fri Mar 25, 2022

REDWOOD CITY, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on...

JSPR : 22.78 (-1.56%)

Barchart Exclusives

What's the Stock Price Forecast for Uber? Barchart - 5 minutes ago
Uber is now much more than just a ride-hailing service, and could potentially hit its Street-high price target - though the stock isn't cheap at current levels. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot